CA19‐9 as a Screening and Diagnostic Tool in Symptomatic Patients: The Japanese Experience
CA19‐9 as a Screening and Diagnostic Tool in Symptomatic Patients: The Japanese Experience
复制标题
CA19‐9 作为有症状患者的筛查和诊断工具：日本经验
作者：
K. Satake;T. Takeuchi;T. Homma;H. Ozaki
虽然胰腺癌的预后普遍较差，但日本胰腺癌登记处在1992年报告称，胰腺癌切除后的存活率远远高于保守治疗。T1和T2胰腺肿瘤比T3和T4肿瘤更容易切除，未切除的T2、T3和T4肿瘤的5年生存率为0%。这些发现强调了早期诊断可切除胰腺癌的重要性。CA19-9在检测晚期胰腺癌方面表现出令人满意的敏感性；我们试图确定CA19-9作为早期癌症筛查计划的一部分的有效性。使用弹性蛋白酶1、CA19-9和超声检查，我们开发并测试了一个大规模筛查程序，对有腹部主诉和没有腹部主诉的患者进行筛查。
Although the prognosis for pancreatic cancer is generally poor, the Japanese Pancreatic Cancer Register reported in 1992 that the survival rate for resected pancreatic cancer was much higher than that for more conservative treatment. T1 and T2 pancreatic tumors are much more frequently resectable than are T3 and T4 tumors, and the 5-year survival rate for unresected T2, T3, and T4 cases is 0%. These findings emphasize the importance of early diagnosis of resectable pancreatic cancer. CA19-9 has shown satisfactory sensitivity in detecting advanced pancreatic cancer; we sought to determine the effectiveness of CA19-9 as part of a screening program for early cancer. Using elastase 1, CA19-9, and ultrasonography, we developed and tested a program of mass screening on persons presenting with and without abdominal complaints.